Thera-SAbDab

SIMTUZUMAB

>   Structural Summary
TherapeuticSimtuzumab
TargetLOXL2
Heavy ChainQVQLVQSGAEVKKPGASVKVSCKASGYAFTYYLIEWVRQAPGQGLEWIGVINPGSGGTNYNEKFKGRATITADKSTSTAYMELSSLRSEDTAVYFCARNWMNFDYWGQGTTVTVSS
Light ChainDIVMTQTPLSLSVTPGQPASISCRSSKSLLHSNGNTYLYWFLQKPGQSPQFLIYRMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQHLEYPYTFGGGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG4
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Discontinued
Recorded Developmental Technologyna
INN Year Proposed2012
INN Year Recommended2013
Companies InvolvedArresto Biosciences, Gilead Sciences
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedColorectal cancer, Hepatic fibrosis, Idiopathic pulmonary fibrosis, Liver cirrhosis, Myelofibrosis, Non-alcoholic steatohepatitis, Pancreatic cancer, Primary sclerosing cholangitis
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]